Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms

Leuk Res. 2010 Oct;34(10):1390-4. doi: 10.1016/j.leukres.2010.01.028. Epub 2010 Feb 18.

Abstract

We evaluated the NOD/SCID engraftment of CD34(+) cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34(+) cells were transplanted intra-femorally. In the injected BM, successful engraftment (>0.1%) occurred in 8/26 mice transplanted with CD34+ cells from 5/13 PV patients (median: 4.26%, range: 0.3-5.56%), in contrast to 0/14 mice from 9 SP patients (P=0.017). The engrafting PV cells were of multi-lineage. JAK2V617F/total JAK2 ratios decreased after transplantation (initial: 65.9% versus 6-week: 13.0%, P=0.001). Essential thrombocythemia (ET) BM cells also exhibited a similar decrease in JAK2V617F clone. The results suggested that events in addition to JAK2V617F are involved in the pathogenesis of PV and ET.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Antigens, CD34 / analysis*
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Janus Kinase 2 / genetics*
  • Male
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Middle Aged
  • Mutation*
  • Polycythemia Vera / etiology
  • Polycythemia Vera / genetics*
  • Primary Myelofibrosis / etiology
  • Primary Myelofibrosis / genetics*
  • Thrombocythemia, Essential / etiology
  • Thrombocythemia, Essential / genetics*

Substances

  • Antigens, CD34
  • JAK2 protein, human
  • Janus Kinase 2